Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy ...

professor of neurology at the University of Minnesota Medical School and head of the GBS | CIDP Foundation International's Global Medical Advisory Board. "Our new report mapping the patient ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) is expected to issue its quarterly earnings data after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

That's also why we're advancing empasiprubart in CIDP despite the fact that we printed the highest response rate average 70%. There is a 30% of patients which have a medical need and were not ...

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S?1117, a novel engineered Fc-fused ...

CONSHOHOCKEN, PA — The GBS | CIDP Foundation International has unveiled ... professor of neurology at the University of Minnesota Medical School and head of the Foundation’s Global Medical ...

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting ...